BriaCell's Strategic Share Consolidation Announcement
BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW, BCTXZ, TSX: BCT), recognized as a pioneering entity in the realm of biotechnology, has unveiled exciting developments regarding its share consolidation initiative. This pivotal step undertaken by the company is designed to facilitate compliance with the listing standards of The Nasdaq Capital Market.
The Consolidation Details
Approved by the board of directors, the share consolidation will involve a conversion ratio of one (1) post-Consolidation Common Share for every ten (10) pre-Consolidation Common Shares. This decision reflects BriaCell's commitment to ensuring stability and adherence to market listing requirements. The consolidation aims to enhance the trading visibility and liquidity of its shares, offering a more robust trading environment for investors.
Expected Effective Date and Trading Continuation
The anticipated effective date for this consolidation is forthcoming, with expectations set to align with the schedules on the Toronto Stock Exchange (TSX) and Nasdaq. Once this action takes effect, trading of the consolidated shares is expected to commence seamlessly, allowing current investors to retain confidence in their holdings.
Handling Fractional Shares
An important aspect of the consolidation is the treatment of fractional shares. Shareholders will notice that any fractional Common Shares remaining post-Consolidation will be addressed carefully. Shares that amount to less than half a Common Share will face cancellation, while those equal to or greater than half a share will be rounded up to one full Common Share, ensuring equity among investors.
Shareholder Communication and Instructions
To keep shareholders well-informed, BriaCell plans to send out letters of transmittal via Computershare Investor Services Inc., its designated transfer agent. These letters will outline the steps necessary for the exchange of Common Shares, ensuring a clear process following the consolidation. Shareholders are encouraged to verify their status and follow the provided instructions promptly.
Long-Term Vision of BriaCell
BriaCell continues to be at the forefront of innovation in cancer treatment through its cutting-edge immunotherapy solutions. The company’s focus on enhancing shareholder value aligns with its mission to develop transformative therapies for cancer care, showcasing a commitment to advancing medical science. By consolidating shares, BriaCell not only reinforces its dedication to regulatory compliance but also strives to create a more favorable trading environment.
Contacting BriaCell for More Information
For shareholders seeking additional insights about the consolidation process, BriaCell encourages open lines of communication. The management team, led by President and CEO Dr. William V. Williams, is readily available to address any inquiries. Engaging with the company can provide shareholders peace of mind during this time of transition.
Frequently Asked Questions
What is BriaCell's share consolidation?
BriaCell's share consolidation is a corporate action where multiple shares are converted into a smaller number, enhancing trading compliance and liquidity.
When will the share consolidation take effect?
The consolidation is anticipated to take effect soon but requires final confirmation from the relevant exchanges.
How will fractional shares be handled during the consolidation?
Fractional shares below half a share will be canceled, while those equal to or above will be rounded up to the nearest whole share.
What should shareholders expect after the consolidation?
Shareholders will receive a letter detailing how to exchange their shares and what to expect moving forward with their holdings.
How can shareholders contact BriaCell for inquiries?
Shareholders can reach out to BriaCell by contacting Dr. William V. Williams or the investor relations team via the provided email addresses.
